Septerna (NASDAQ:SEPN) Price Target Raised to $65.00

Septerna (NASDAQ:SEPN) had its price target lifted by equities researchers at Guggenheim from $51.00 to $65.00 in a report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s target price would indicate a potential upside of 32.79% from the company’s current price.

SEPN has been the subject of several other research reports. HC Wainwright raised their target price on Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. boosted their price target on Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Raymond James Financial restated a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. Finally, Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.22.

Septerna Stock Up 3.4%

Shares of NASDAQ SEPN traded up $1.60 during trading on Friday, reaching $48.95. The company had a trading volume of 29,031 shares, compared to its average volume of 362,267. The stock has a market cap of $2.28 billion, a P/E ratio of -91.07 and a beta of 2.20. The company’s fifty day moving average price is $39.36 and its 200-day moving average price is $32.48. Septerna has a 12 month low of $17.55 and a 12 month high of $51.10.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The firm had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. As a group, equities analysts predict that Septerna will post -1.41 earnings per share for the current year.

Insider Activity

In other news, SVP Daniel Long sold 3,333 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at $3,647,265.96. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total value of $149,640.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $6,517,158.69. This represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 32,333 shares of company stock worth $1,375,727. Insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. TRV GP V LLC bought a new position in Septerna during the 2nd quarter valued at approximately $208,160,143. TRV GP VI LLC bought a new stake in shares of Septerna in the 2nd quarter worth approximately $141,048,460. BlackRock Inc. bought a new stake in shares of Septerna in the 2nd quarter worth approximately $64,706,000. Jupiter Topco LLC bought a new stake in shares of Septerna in the 2nd quarter worth approximately $43,723,000. Finally, Primecap Management Co. CA purchased a new position in shares of Septerna during the second quarter valued at approximately $39,096,000.

Septerna Company Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.